Talia Alperin

An Answer to Cancer: Powering Progress with Lustgarten

Thank you for visiting my fundraising page! When Lustgarten was founded in 1998, the five-year survival rate of pancreatic cancer was around 4%. Now, in 2026, it is around 12%, and thanks to recent developments, it is likely to increase significantly. Lustgarten is funding numerous researchers investigating new early detection technologies, treatments and cures. With your support, we are seeing breakthroughs in pancreatic cancer treatment at this very moment, such as the development of cancer vaccines and daraxonrasib, a revolutionary medication neutralizing aggressive mutations. 

For the past several years, I have fundraised for Lustgarten because I lost many family members to this disease. Lustgarten is the nation’s largest private funder of pancreatic cancer research, and thanks to separate funding of administrative expenses, 100% of your donation goes to pancreatic cancer research–research led by Lustgarten and powered by you! Together, we will raise more money for research advancements than I ever could alone. Please consider supporting my fundraiser; every dollar brings patients closer to cures. Thank you!